IGKV3 11 | ENSG00000241351 | NCBI 28914

Details for: IGKV3 11

Gene ID: 28914

Gene Type: Other - A known gene or region type that lacks a specific category. Includes immunoglobulin (Ig), T-cell receptor (TCR) gene segments, and repetitive elements.

Symbol: IGKV3 11

Ensembl ID: ENSG00000241351

Description: immunoglobulin kappa variable 3-11

Cell Significance Landscape

Display Count:

Associated with

Adaptive immune system
(R-HSA-1280218)
Anti-inflammatory response favouring leishmania parasite infection
(R-HSA-9662851)
Antigen activates b cell receptor (bcr) leading to generation of second messengers
(R-HSA-983695)
Binding and uptake of ligands by scavenger receptors
(R-HSA-2173782)
Cd22 mediated bcr regulation
(R-HSA-5690714)
Cell surface interactions at the vascular wall
(R-HSA-202733)
Classical antibody-mediated complement activation
(R-HSA-173623)
Complement cascade
(R-HSA-166658)
Creation of c4 and c2 activators
(R-HSA-166786)
Disease
(R-HSA-1643685)
Fc epsilon receptor (fceri) signaling
(R-HSA-2454202)
Fceri mediated ca+2 mobilization
(R-HSA-2871809)
Fceri mediated mapk activation
(R-HSA-2871796)
Fceri mediated nf-kb activation
(R-HSA-2871837)
Fcgamma receptor (fcgr) dependent phagocytosis
(R-HSA-2029480)
Fcgr3a-mediated il10 synthesis
(R-HSA-9664323)
Fcgr3a-mediated phagocytosis
(R-HSA-9664422)
Fcgr activation
(R-HSA-2029481)
Hemostasis
(R-HSA-109582)
Immune system
(R-HSA-168256)
Immunoregulatory interactions between a lymphoid and a non-lymphoid cell
(R-HSA-198933)
Infectious disease
(R-HSA-5663205)
Initial triggering of complement
(R-HSA-166663)
Innate immune system
(R-HSA-168249)
Leishmania infection
(R-HSA-9658195)
Leishmania parasite growth and survival
(R-HSA-9664433)
Leishmania phagocytosis
(R-HSA-9664417)
Parasite infection
(R-HSA-9664407)
Parasitic infection pathways
(R-HSA-9824443)
Potential therapeutics for sars
(R-HSA-9679191)
Regulation of actin dynamics for phagocytic cup formation
(R-HSA-2029482)
Regulation of complement cascade
(R-HSA-977606)
Role of lat2/ntal/lab on calcium mobilization
(R-HSA-2730905)
Role of phospholipids in phagocytosis
(R-HSA-2029485)
Sars-cov infections
(R-HSA-9679506)
Scavenging of heme from plasma
(R-HSA-2168880)
Signaling by the b cell receptor (bcr)
(R-HSA-983705)
Vesicle-mediated transport
(R-HSA-5653656)
Viral infection pathways
(R-HSA-9824446)

Significant Cells

Cell Significance Index (CSI) scores for the chosen context(s)

class switched memory B cell CL0000972

CSI 23.82

rCSI 17.78%

PRS 99.92
immature B cell CL0000816

CSI 21.02

rCSI 15.62%

PRS 99.98
unswitched memory B cell CL0000970

CSI 12.88

rCSI 10.83%

PRS 99.97
B cell CL0000236

CSI 11.86

rCSI 15.87%

PRS 99.49
IgA plasma cell CL0000987

CSI 11.75

rCSI 12.03%

PRS 99.19
plasmablast CL0000980

CSI 9.64

rCSI 7.58%

PRS 99.67
non-classical monocyte CL0000875

CSI 7.46

rCSI 11.95%

PRS 99.78
erythrocyte CL0000232

CSI 5.53

rCSI 12.55%

PRS 99.64
IgG plasma cell CL0000985

CSI 4.25

rCSI 5.09%

PRS 99.71

Cell ID: Standard Cell Ontology term used for mapping and comparing cells across experiments. Ensures consistency in analyzing cellular functions across tissues.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this specific cell.

Network Configuration

Explore relationships of the current gene. Select an Interaction Source: 'ONTOLOGY' for shared pathways (GO/Reactome) or 'STRING' for protein-protein interactions. Further refine by selecting context genes and comparing Cell Significance Index (CSI) scores between baseline and target cell types and their specific contexts.

Context Genes (max 20):

Interaction Source:

Pathway Categories (for ONTOLOGY source):

Baseline Cell Type:

Baseline Cell Context(s): Comma-separated if multiple.

Target Cell Type:

Target Cell Context(s): Comma-separated if multiple.

Legend:

Query Gene
Node Color (Target Cell CSI, relative to current network):
- Very High
- High
- Medium
- Low
- Very Low
- CSI N/A
Node Size: Proportional to Target Cell CSI magnitude
STRING PPI Edge
Shared Pathway Edge (ONTOLOGY)

Loading network (please wait)...

Other Information

This section provides additional information about the gene, including a description generated by an AI language model and details about associated proteins.

Description

## Summary [IGKV3-11](/details-gene/28914) is an immunoglobulin kappa variable gene located on chromosome 2. It encodes a variable (V) region segment that is a critical component of the antibody light chain. Its expression profile is overwhelmingly specific to the B cell lineage, with exceptionally high significance in [class switched memory B cell](/details-cell/CL0000972)s and [immature B cell](/details-cell/CL0000816)s. Functionally, [IGKV3-11](/details-gene/28914) is integral to the adaptive immune system, participating directly in B cell receptor (BCR) signaling and the formation of secreted antibodies involved in humoral immunity. Its involvement in numerous immune pathways, including complement activation and Fc receptor signaling, underscores its central role in pathogen defense and immune regulation. ## Cellular Roles and Expression Landscape The expression pattern of [IGKV3-11](/details-gene/28914) firmly establishes it as a key gene in the development and function of the humoral immune system. **Overall**, the gene shows the highest significance in cells of the B lymphocyte lineage, highlighting its role throughout their lifecycle. It is most significant in mature and memory B cell populations, including [class switched memory B cell](/details-cell/CL0000972) (CSI: 23.82) and [unswitched memory B cell](/details-cell/CL0000970) (CSI: 12.88), which is consistent with its function in forming the antigen-binding portion of antibodies produced during secondary immune responses. High significance in [immature B cell](/details-cell/CL0000816)s (CSI: 21.02) and generic [B cell](/details-cell/CL0000236)s (CSI: 11.86) indicates its early and continuous involvement in generating the primary antibody repertoire. Furthermore, its high significance in antibody-secreting cells, such as [IgA plasma cell](/details-cell/CL0000987)s (CSI: 11.75), [plasmablast](/details-cell/CL0000980)s (CSI: 9.64), and [IgG plasma cell](/details-cell/CL0000985)s (CSI: 4.25), directly reflects its role as a building block for secreted immunoglobulins. Interestingly, [IGKV3-11](/details-gene/28914) also shows notable significance in [non-classical monocyte](/details-cell/CL0000875)s (CSI: 7.46), which may be due to the presence of surface-bound antibodies on their Fc receptors or could suggest a more complex, uncharacterized role. ## Pathways and Molecular Function The functional annotations for [IGKV3-11](/details-gene/28914) are tightly aligned with its expression in B lymphocytes and its role in antibody production. The gene is a central component of the [Adaptive immune system](/details-pathway/R-HSA-1280218) and, more specifically, [Signaling by the b cell receptor (bcr)](/details-pathway/R-HSA-983705). Its involvement in pathways like [Antigen activates b cell receptor (bcr) leading to generation of second messengers](/details-pathway/R-HSA-983695) and [Cd22 mediated bcr regulation](/details-pathway/R-HSA-5690714) is consistent with its function in the V(D)J recombination product that forms the antigen-binding site of the BCR. Once expressed as part of a secreted antibody, proteins containing the [IGKV3-11](/details-gene/28914) segment execute effector functions through pathways such as [Classical antibody-mediated complement activation](/details-pathway/R-HSA-173623) and [Fcgamma receptor (fcgr) dependent phagocytosis](/details-pathway/R-HSA-2029480). This highlights its dual role in both antigen recognition and the subsequent clearance of pathogens. The extensive listing in pathways related to infectious diseases, including [Leishmania infection](/details-pathway/R-HSA-9658195) and [Sars-cov infections](/details-pathway/R-HSA-9679506), demonstrates the direct relevance of antibodies utilizing this gene segment in host defense. ## Research Directions The specific usage of V-gene segments like [IGKV3-11](/details-gene/28914) can influence antibody affinity, stability, and polyreactivity, making it a subject of interest in both normal and pathological immune responses. ### Proposed Hypotheses 1. **Preferential Selection in Autoimmunity:** Given its high expression across B cell development, it is hypothesized that the [IGKV3-11](/details-gene/28914) V-gene segment possesses structural characteristics that make it more likely to be selected in certain autoimmune diseases, such as lupus or rheumatoid arthritis, where B cell tolerance is broken. This could be due to an intrinsic capacity to bind self-antigens. 2. **Role in Monocyte Function:** The significant expression score in [non-classical monocyte](/details-cell/CL0000875)s is unusual for an immunoglobulin gene. It is hypothesized that this is not simply due to cytophilic antibodies bound to Fc receptors but reflects active, albeit low-level, transcription within these cells. This transcribed product could potentially function in an intracellular regulatory capacity or contribute to a localized immune environment. ### Experimental Approach To test the hypothesis regarding monocyte expression (Hypothesis 2), a multi-faceted approach could be employed. First, [non-classical monocyte](/details-cell/CL0000875)s would be purified from healthy human donors using fluorescence-activated cell sorting (FACS). To distinguish between endogenous transcription and external antibody binding, single-cell RNA sequencing (scRNA-seq) with analysis of nascent, unspliced pre-mRNA transcripts (e.g., via scVelo) could confirm active transcription of the [IGKV3-11](/details-gene/28914) locus within the monocytes. Concurrently, highly sensitive protein detection methods like proximity ligation assay (PLA) could be used to determine if the IGKV3-11 protein is located intracellularly or is restricted to the cell surface, providing evidence for its site of action. ### Therapeutic Potential As a germline gene segment, [IGKV3-11](/details-gene/28914) itself is not a conventional therapeutic target for inhibition. However, its product—the V-region of an antibody—holds significant potential. If specific B-cell malignancies, such as chronic lymphocytic leukemia (CLL) or certain lymphomas, demonstrate clonal expansion using the [IGKV3-11](/details-gene/28914) segment, the unique antigen-binding site (idiotype) of that malignant BCR could become a target. This would allow for the development of highly specific anti-idiotype antibodies or CAR-T cells, representing a personalized medicine approach that targets only the cancerous B cells while sparing healthy ones.

Disclaimer: This in-silico analysis is generated by an AI language model and may contain inaccuracies or hallucinations. However, it is cross-referenced with curated gene expression data from major biological sources. Please verify the information before use.